Ideal Pharma Peptide USA: Launches Industrial Production of Short Peptides in the United States

Ideal Pharma Peptide USA has inaugurated its industrial production of short peptides in the United States, marking a significant milestone in the field of pharmaceutical manufacturing.

The company’s first short peptide produced on American soil is a specialized peptide aimed at restoring the barrier functions of the gastrointestinal tract, known as IPH AG peptide.

IPH AG is a water-soluble dipeptide consisting of two linked amino acid residues, based on the platform of maternal amino acids. This dipeptide acts locally in the gastrointestinal tract, protecting the integrity of the intestinal mucosa and maintaining intestinal barrier functions. It reduces bacterial translocation, the risk of infection, inflammatory damage, and alleviates symptoms associated with infections such as diarrhea, dehydration, malabsorption, and electrolyte imbalances.

Upon absorption, the peptide also suppresses the catabolism of muscle protein, particularly of smooth muscles (internal organ muscles). Another crucial function of this dipeptide is its unique ability to enhance the bioavailability of other ingredients with which it enters the body. It influences the absorption function of active components, such as minerals—especially calcium—and vitamins, predominantly of groups D and B. It also has a prolonged effect on the speed and integrity of the absorption of polyunsaturated fatty acids, which are part of cell membranes and blood vessels and are not synthesized in sufficient quantities by the body.

IPH AG dipeptide can confidently be classified as a tissue-specific peptide of the gastrointestinal tract, performing barrier functions and acting as a conduit for active components, thus ensuring enhanced bioavailability of standard forms of minerals and vitamins that enter the body with it.